Publication
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (11)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 11
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugEverolimuscivic_curation1.00
- drugMTOR Kinase Inhibitor PP242civic_curation1.00
- geneERBB2civic_curation1.00
- genePIK3CAcivic_curation1.00
- genePIK3R1civic_curation1.00
- genePTENcivic_curation1.00
- variantERBB2 Amplificationcivic_curation1.00
- variantPIK3CA Mutationcivic_curation1.00
- variantPIK3R1 Mutationcivic_curation1.00
- variantPTEN Losscivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 21358673
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 Amplification1 | ||||||||
| MTOR Kinase Inhibitor PP242 | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1613In a panel of 31 breast cancer cell lines with varied mutation backgrounds, 10 cell lines harbored HER2 (ERBB2) amplification. Sensitivity to the mTORC1/2 inhibitor PP242 was assessed, and 8/10 HER2 p… (full text at CIViC) PMID 21358673 · Weigelt et al., 2011 · Open in CIViC | civic |
| PIK3CA Mutation1 | ||||||||
| Everolimus + MTOR Kinase Inhibitor PP242Substitutes | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1610A panel of 31 breast cancer cell lines was tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/mTORC2 inhibitor PP242. Inhibitor concentrations for 50% survival fraction (SF50) were measu… (full text at CIViC) PMID 21358673 · Weigelt et al., 2011 · Open in CIViC | civic |
| PIK3R1 Mutation1 | ||||||||
| MTOR Kinase Inhibitor PP242 | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1612Sensitivity to mTORC1/2 inhibitor PP242 was assessed in a panel of breast cancer cell lines with various mutation backgrounds. PTEN and PIK3CA mutations were heavily represented in the panel. However,… (full text at CIViC) PMID 21358673 · Weigelt et al., 2011 · Open in CIViC | civic |
| PTEN Loss1 | ||||||||
| Everolimus + MTOR Kinase Inhibitor PP242Substitutes | Malignant Breast Neoplasm | Predictive | D | Does Not Support Sensitivity Response | 3 | accepted | EID1611In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function. Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation w… (full text at CIViC) PMID 21358673 · Weigelt et al., 2011 · Open in CIViC | civic |